Basic Information



Gene symbol LIPF Synonyms GL, HGL, HLAL Type of gene protein-coding
Description lipase F, gastric type

Gene symbol LAMP3 Synonyms CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3, TSC403 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description lysosomal associated membrane protein 3

Gene symbol UL128 Synonyms None Type of gene protein-coding
Description contains signal peptide; similar to CC chemokines; complexed with envelope glycoproteins H and L; essential in non-fibroblast cells; involved in cell entry

Gene symbol UL130 Synonyms None Type of gene protein-coding
Description envelope glycoprotein UL130

Gene symbol UL131A Synonyms None Type of gene protein-coding
Description envelope protein UL131A

Gene symbol UL83 Synonyms None Type of gene protein-coding
Description tegument protein pp65

GTO ID GTC1841
Trial ID NCT03382405
Disease Human Cytomegalovirus Infection
Altered gene gB|gH|gL|UL128|UL130|UL131A|UL83|LAMP
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment mRNA-1647|mRNA-1443
PhasePhase1
Recruitment statusCompleted
TitleA Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 When Administered to Healthy Adults
Year2017
CountryUnited States
Company sponsorModernaTX, Inc.
Other ID(s)mRNA-1647/mRNA-1443-P101
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: CMV-seronegative participants_mRNA-1647_dose level 1
Administration route intramuscular injection
Dosage mRNA-1647, 30 μg
Pts 4
Age Adult
References PMID: 38478705 | 38324766
Cohort2: CMV-seronegative participants_mRNA-1647_dose level 2
Administration route intramuscular injection
Dosage mRNA-1647, 90 μg
Pts 4
Age Adult
References PMID: 38478705 | 38324766
Cohort3: CMV-seronegative participants_mRNA-1647_dose level 3
Administration route intramuscular injection
Dosage mRNA-1647, 180 µg
Pts 4
Age Adult
References PMID: 38478705 | 38324766
Cohort4: CMV-seronegative participants_Placebo
Administration route intramuscular injection
Pts 3
Age Adult
References PMID: 38478705 | 38324766
Cohort5: mRNA-1443
Administration route intramuscular injection
Dosage 40 μg
Pts 1
Age Adult
References PMID: 38478705 | 38324766
Cohort6: CMV-seronegative and CMV-seropositive participants_mRNA-1647_dose level 1
Administration route intramuscular injection
Dosage mRNA-1647, 30 μg
Pts 30
Age Adult
References PMID: 38478705 | 38324766
Cohort7: CMV-seronegative and CMV-seropositive participants_mRNA-1647_dose level 2
Administration route intramuscular injection
Dosage mRNA-1647, 90 μg
Pts 30
Age Adult
References PMID: 38478705 | 38324766
Cohort8: CMV-seronegative and CMV-seropositive participants_mRNA-1647_dose level 3
Administration route intramuscular injection
Dosage mRNA-1647, 180 µg
Pts 29
Age Adult
References PMID: 38478705 | 38324766
Cohort9: CMV-seronegative and CMV-seropositive participants_Placebo
Administration route intramuscular injection
Pts 30
Age Adult
References PMID: 38478705 | 38324766
Cohort10: mRNA-1647_dose level 4
Administration route intramuscular injection
Dosage mRNA-1647, 300 μg
Pts 29
Age Adult
References PMID: 38478705 | 38324766

Relationship Graph

Overview of Knowledge Graph